ALD in China represents a pressing public health issue influenced by complex social and cultural factors. The increasing prevalence of the disease, coupled with severe complications and a lack of ...
VANCOUVER — Autologous hematopoietic stem cell (HSC) gene therapy may offer a safe and effective alternative to allogeneic bone marrow transplant for patients with cerebral adrenoleukodystrophy, ...
Alcohol-related liver disease (ALD) is a major cause of morbidity and premature mortality around the world, with a substantial cost to individuals and to health-care systems. The incidence of ALD is ...
NeuroVia Closes Series A Financing Round of $14M to Develop Novel Treatment Option for X-ALD Disease
CAMBRIDGE, Mass.--(BUSINESS WIRE)--NeuroVia, Inc., a biopharmaceutical company focused on developing innovative therapies for rare genetic neurological diseases, announced the closing of a Series A ...
A study published in the Clinical Gastroenterology and Hepatology journal, and led by UNC School of Medicine researchers, found that alcohol-associated liver disease (ALD) mortality accelerated during ...
ALD is a common chronic liver disease that frequently leads to cirrhosis 1. With rising incidence rates, ALD has become the leading indication of liver transplantation 2 and is responsible for more ...
Susan-Elizabeth Littlefield loves sharing the good news. She hosts a show on Sunday mornings based on local "positivity and empowerment," leading right into CBS Sunday Morning. MINNEAPOLIS – There has ...
A study combining analysis of patient samples with mice studies has identified new drug targets for alcohol-related liver disease, which, currently, doctors can only treat by transplant. Share on ...
A newly published review in eGastroenterology compiles recent research on alcohol-associated liver disease (ALD), offering an overview of its pathogenesis and efforts to better understand this ...
GAITHERSBURG, Md., July 09, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and ...
LYON, France--(BUSINESS WIRE)--POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results